Consensus Cara Therapeutics, Inc.

Equities

CARA

US1407551092

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-18 pm EDT			5-day change	1st Jan Change
0.69 ^USD	-5.72%		-14.88%	-7.13%

Mar. 22	Cara Therapeutics, Inc. Announces Resignation of Dr. Joana Goncalves as Chief Medical Officer, Effective April 16, 2024	CI
Mar. 06	Canaccord Genuity Adjusts Cara Therapeutics Price Target to $10 From $11, Maintains Buy Rating	MT

Evolution of the average Target Price on Cara Therapeutics, Inc.

Price target over the last 5 years

History of analyst recommendation changes

415c864384a6.a36Di_-D0vqvZpZ37PBTGnEwvxy39Hd0oaXvBx7Bj10.DQ3EzpXTg4L9DPQm3YY7TShD_ST5wT8j19-BamqS5wkAKuW7zc6Yme4hpg~3aec18c67bfacdd5e615eeac1c91983b

Analyst Recommendations on Cara Therapeutics, Inc.

Canaccord Genuity Adjusts Cara Therapeutics Price Target to $10 From $11, Maintains Buy Rating	Mar. 06	MT
HC Wainwright Adjusts Price Target on Cara Therapeutics to $2.50 From $7, Keeps Buy Rating	Dec. 19	MT
Needham Adjusts Price Target on Cara Therapeutics to $6 From $22, Maintains Buy Rating	Dec. 18	MT
Piper Sandler Downgrades Cara Therapeutics to Neutral From Overweight, Cuts Price Target to $1 From $12	Nov. 14	MT
HC Wainwright Adjusts Price Target on Cara Therapeutics to $7 From $15, Keeps Buy Rating	23-10-19	MT
HC Wainwright Lowers Price Target on Cara Therapeutics to $15 From $20, Maintains Buy Rating	23-05-16	MT
BofA Securities Adjusts Price Target on Cara Therapeutics to $4 From $6, Maintains Underperform Rating	23-05-16	MT
BofA Securities Downgrades Cara Therapeutics to Underperform From Neutral, Cuts PT to $6 From $13 on Lower Peak Sales Forecast of Drug	23-03-08	MT
BofA Downgrades Cara Therapeutics to Underperform From Neutral, Adjusts Price Target to $6 From $13	23-03-08	MT
Canaccord Genuity Adjusts Price Target on Cara Therapeutics to $25 From $29, Maintains Buy Rating	23-03-07	MT
HC Wainwright Adjusts Price Target on Cara Therapeutics to $20 From $25, Keeps Buy Rating	23-03-07	MT
Piper Sandler Adjusts Price Target on Cara Therapeutics to $13 From $25, Keeps Overweight Rating	23-03-07	MT
JPMorgan Adjusts Price Target on Cara Therapeutics to $16 From $19, Maintains Overweight Rating	23-03-07	MT
Needham Cuts Price Target on Cara Therapeutics to $22 From $26, Maintains Buy Rating	23-03-07	MT
HC Wainwright Adjusts Price Target on Cara Therapeutics to $25 From $30, Maintains Buy Rating	23-02-14	MT
Canaccord Genuity Adjusts Cara Therapeutics' Price Target to $29 from $33, Keeps Buy Rating	22-03-14	MT
HC Wainwright Adjusts Cara Therapeutics' Price Target to $30 from $35, Keeps Buy Rating	22-03-14	MT
JPMorgan Raises Cara Therapeutics to Overweight From Neutral, Price Target to $20 From $17	22-03-08	MT
CARA THERAPEUTICS : HC Wainwright Adjusts Price Target on Cara Therapeutics to $35 From $33, Maintains Buy Rating	21-08-24	MT
CARA THERAPEUTICS : JPMorgan Starts Cara Therapeutics at Neutral With $16 Price Target	21-08-03	MT
CARA THERAPEUTICS : Needham & Co Adjusts Cara Therapeutics PT to $26 From $35, Maintains Buy Rating	21-04-29	MT